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Tuberculosis (TB) is an important cause of childhood morbidity, mortality and death. The incidence 
of childhood TB has increased in low and middle income countries.[1] This resurgence is partly 
attributed to the coexisting burden of human immunodeficiency virus (HIV) disease [2], which is 
most pronounced in Sub-Saharan Africa. At the end of 2009 an estimated 33.3 million adults and 2.5 
million children under 15 years were living with HIV.[3] In many HIV endemic areas there is a co-
existing high TB prevalence.[4] 
Dual infection with TB has an important impact on HIV disease. TB accelerates the progression of HIV 
disease by increasing viral replication.[5] It is a common cause of acute pneumonia in African HIV-
infected children [6, 7] and frequently results in chronic lung disease including bronchiectasis.[8] TB 
is a common cause of death in HIV-infected children.[9] Antituberculosis drugs, such as rifampicin 
(RIF), have deleterious drug interactions with anti-retroviral therapy. Rifampicin, an inducer of 
cytochrome P450 CYP3A, decreases the concentration of both the protease inhibitors and non-
nucleoside reverse transcriptase inhibitors, leading to sub-therapeutic levels, with an increased risk 
of inadequate viral suppression and drug resistance. The large pill burden of two multiple drug 
regimens increases the risk of adverse events such as liver toxicity and increases the likelihood of 
poorer adherence.[10]  
Conversely, HIV infection impacts on TB disease. HIV infected children have a higher risk of 
developing primary TB as compared to seronegative children.[11] The clinical diagnosis of TB is more 














Furthermore tuberculin skin testing is less sensitive due to immunosuppression and chest 
radiography less specific.[9, 12] The outcome of HIV infected versus HIV uninfected children with TB 
co-infection is poorer, with mortality increased by six fold in HIV-infected children.[12, 13] The cure 
rate of TB in HIV infected children is significantly lower than that of HIV uninfected children [11, 12] 
and there is a higher rate of recurrence.[14] HIV-infected children stable on highly active 
antiretroviral therapy (HAART) are less likely to develop TB and have a better outcome than those 
not on HAART. However, the initiation of highly active antiretroviral therapy (HAART) in the setting 
of TB co-infection can lead to a paradoxical worsening of TB as a consequence of the 'immune 
reconstitution syndrome'.[15, 16]  
Hence, preventing TB infection and disease in HIV-infected children is potentially an important 
public health intervention. Isoniazid (INH) has been used successfully as preventive therapy in HIV 
uninfected children at risk of TB disease.[17] Preventive therapy has been reported to be effective 
for prevention of TB disease in HIV-infected adults with a positive tuberculin skin test [18], reducing 
the risk of disease by 36%. A double blind placebo controlled trial investigating the efficacy of INH 
prophylaxis in HIV-infected children before HAART was widely available reported a significant impact 
on mortality and TB incidence - the mortality rate (32, 12.2%) was significantly lower in those on INH 
compared with placebo [11(8%) vs. 21(16%), HR 0.46 (95% CI 0.22 - 0.95), p=0.015], indicating a 
reduction in mortality of more than 50%. [18] The incidence of TB (10.8%) was also significantly 
lower in those on INH (3.8%) versus placebo (9.9%), HR 0.28 [95% CI 0.1 to 0.78], p=0.005), 
representing a 70% reduction in the incidence of TB. [18].  
 
Thus INH may be an effective public health intervention for HIV-infected children living in high TB 
prevalence areas. However HAART itself protects against TB disease in adults and children. The 
efficacy of isoniazid preventive therapy (IPT) in preventing TB in the setting of wider availability of 
HAART for children in South Africa is not known. Other areas requiring further study include the long 
term protective efficacy of INH, the optimal duration of prophylaxis, and long term safety. Potential 
concerns with using IPT are the need to exclude TB disease in children before initiating INH 
preventive therapy and the impact this may have on antituberculosis drug sensitivity.  
 
Aim: 
To assess the efficacy, tolerability and safety of isoniazid preventive therapy compared to placebo in 
HIV-infected children on highly active antiretroviral therapy living in a high TB prevalence area. 
Objectives: 
To compare the impact of two different INH preventive regimens (daily or thrice weekly) on 
 Incidence of culture confirmed and probable TB 
 Mortality 
 INH resistance with culture confirmed TB 




A longitudinal prospective double-blind placebo controlled trial comparing INH versus placebo in 
HIV-infected children attending Red Cross Children’s Hospital or Tygerberg Children’s Hospital. 
Enrolments began July 2006.  
Inclusion criteria will be 
 Weight ≥ 2.5kg 
 Informed consent obtained from parent or legal guardian 
 Resident in Cape Metropole 














 On HAART for ≥ 2 months with ≤ Grade 2 toxicity for liver enzymes and full blood count 
 Adherence to HAART ≥ 90% for all components 
Exclusion criteria will be: 
 Chronic diarrhoea  
 Current use of INH prophylaxis 
 Prior hypersensitivity to INH 
 Severe anaemia (haemoglobin less than 7 gm/dl) 
 Neutropenia (absolute neutrophil count less than 400 cells) 
 Thrombocytopenia (platelet count less than 50 000/ul) 
 Non reversible renal failure 
 Exposure to household TB contact 
 
Tuberculosis will be excluded prior to randomization if not already done within the previous 3 
months. Children will be screened for TB by history taking, Mantoux skin test, chest radiograph and 3 
gastric washings or induced sputum when there are symptoms or new radiological abnormalities 
suggestive of TB. Any child found to have TB will be treated as per national guidelines; once 
treatment has been completed then INH or placebo may be initiated. 
Children will be randomised at study entry to receive either INH or visually identical placebo either 
thrice weekly or daily according to variable blocked randomization lists prepared by the trial 
statistician. Pharmacists will label the trial drugs using sequential numbers from these lists.  The 
dose of INH is 10 mg/kg/dose with a variability of 8-12 mg/kg determined according to whether half 
or quarter tablets are required. Placebo has an identical appearance to INH tablets and will be 
administered in a double blind manner.  
 
Investigations  
At the baseline visit a detailed history, examination and clinical HIV staging will be done, thereafter 
an abbreviated history and examination will be done at each visit. A full blood count (FBC), liver 
function tests (ALT) and urea and electrolytes (U&E) will be performed prior to randomization. 
The absolute number and percentage of CD4 cells and viral load will be measured at study entry and 
then 6 monthly. A complete blood count and ALT will be performed 6 monthly. PPD skin testing will 
be repeated 6 monthly if prior tests are negative. A chest X-ray will be performed yearly to assess 
progression of lung disease; the X-ray will be reported according to a standardised format by a single 
radiologist who is blinded to the prophylactic regimen to which the child has been randomised. 
At each visit, symptoms of adverse reactions to INH prophylaxis will be recorded. Reason for any 
hospitalization will be ascertained by the study team and recorded. Investigations for TB will include 
skin testing, chest X ray and gastric lavage or induced sputum specimens. The diagnosis of confirmed 
or probable TB will be made by the treating doctor and will be subject to review by 2 reviewers using 
the clinical, radiological and laboratory data.  
Patients will be seen monthly for the first 6 months, then 2 monthly thereafter. 
Adherence 
Patients will be provided with an adequate medication supply and will be requested to return empty 
CTX and INH containers. Adherence for INH / placebo and CTX will be assessed through a 7-day 
recall. An adherence questionnaire will be completed three monthly. Adherence to INH prophylaxis 
will also be assessed by checking urine samples for INH metabolites yearly.  
Development of TB during the trial or exposure to a household TB contact 
 If a child develops pulmonary TB while on the study, the randomization code will be broken. If 














will be used. Treatment will be modified according to sensitivities, should M. tuberculosis be 
cultured. If extra-pulmonary TB develops, subjects on placebo will be treated according to 
national guidelines; however, if randomized to INH a fifth drug will be added.  
 The INH prophylactic regimen will be discontinued while the child receives treatment for TB but 
will be resumed once TB treatment has been completed.  
 Children found to have TB will be notified and referred to their closest local TB clinic from where 
contact tracing is also performed  
 HAART will be modified according to Provincial Guidelines  
 If a household contact develops TB, the patient will be tested for TB (Mantoux skin test, chest X-
ray and induced sputum or 3 gastric washings). If this occurs within 6 weeks of enrolment, 
investigations will not be repeated unless clinically indicated (weight loss, fever or cough for 
more than 2 weeks). If the child is not found to have TB, then open-label INH will be given daily 
for 6 months after which the INH/placebo will be restarted. The randomization code will not be 
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PART B: LITERATURE REVIEW 
ISONIAZID PREVENTIVE THERAPY IN HIV INFECTED CHILDREN 
BACKGROUND 
Tuberculosis (TB) is an important cause of childhood morbidity and death, particularly in high TB 
prevalence areas. In 2010 there were an estimated 8 million incident cases of tuberculosis globally, 
1.2 million amongst people living with HIV.[19] The high prevalence of TB is driven in part by the HIV 
epidemic. At the end of 2010 an estimated 34 million adults and children were living with HIV, 68% 
of which live in Sub Saharan Africa.[3] TB and HIV frequently co-exist. The African region accounts for 
26% of the global TB burden and 82% of the TB cases among people living with HIV.[19] In South 
Africa 60% of adult TB cases are living with HIV.[19] Although accurate TB epidemiological data is 
lacking in children due to difficulties in diagnosis and inadequate national notification, childhood TB 
is a reflection of the TB transmission within a community. Hence the burden of childhood TB can be 
expected to be large in areas with high TB prevalence.  
Dual infection with TB has an important impact on HV disease. TB is associated with accelerated 
disease progression [20] and increased HIV viral replication.[5] Exposure of alveolar macrophages 
and lymphocytes from HIV-infected individuals to M tuberculosis in vitro leads to up-regulation of 
HIV viral replication. [5] HIV viral replication was enhanced in the broncho-alveolar lavage samples 
from TB involved as compared to uninvolved lung segments in HIV infected patients. [21] TB is a 
common cause of acute pneumonia in African HIV-infected children [22, 23] and often results in 
chronic lung disease or bronchiectasis.[8, 24, 25] TB is an important cause of death in HIV infected 
children as found in necropsy studies that predate highly active antiretroviral therapy (HAART).[25, 
26]  Tuberculosis drugs, such as Rifampicin, interact with antiretroviral therapy. Rifampicin is an 
inducer of cytochrome P450 CYP3A and decreases the concentration of the protease inhibitors, most 
notably ritonavir and to a lesser extent the non-nucleoside reverse transcriptase inhibitors (NNRTI). 
This leads to sub-therapeutic levels of the antiretroviral drugs and an increased risk of inadequate 
viral suppression and drug resistance.[27, 28] Therefore rifampicin should preferably be used with 
an NNRTI based regimen rather than protease inhibitor-based regimen. If a protease inhibitor is 
used, a ritonavir boosted protease inhibitor is required. In addition the large pill burden of two multi 
drug regimens may increase the risk of adverse events such as nausea and liver toxicity and the 
likelihood of poor adherence.[10] 
 
Conversely, HIV infection impacts on TB disease. HIV infected children have a higher risk of 
developing primary TB as compared to HIV uninfected children.[11]  A recent South African study 
reported a relative risk of developing culture-confirmed TB of 24.2 (95% CI 17 to 34) in HIV-infected 
versus uninfected infants.[29] Diagnosing TB in HIV infected children is difficult as other 
opportunistic infections and HIV itself my mimic TB. Tuberculin skin testing is less sensitive due to 
immunosuppression and chest radiographs are less specific. [12, 24] The outcome of TB in HIV 
infected children is worse than that of HIV uninfected children, with a 6 fold increase in mortality in 
the former.[12, 30] HIV infected infants and children with culture confirmed TB and poor access to 
HAART had a mortality of 21-39%.[29, 31, 32] HIV infected children have a lower cure rate than HIV 
uninfected children.[11, 12] In an Ethiopian cohort of children with TB, the cure rate was 58% for 














infected children. In a South African cohort of HIV-infected children with culture confirmed TB, 16% 
had recurrent disease.[14] This is more than double the expected rate of TB recurrence of 2-7% in 
HIV uninfected patients with drug-susceptible TB who complete current standard short course 
tuberculosis therapy.[33] HIV-infected children on HAART are less likely to develop TB and have a 
better outcome than those not on HAART.[34-36]  However the initiation of HAART in the setting of 
severe immunosuppression and TB-co infection can lead to a paradoxical worsening of TB, the  
immune reconstitution inflammatory syndrome.[16, 37, 38] Moreover the risk of TB in HIV infected 
children on HAART is still higher than that of HIV uninfected children.[39] 
Preventing TB in HIV infected children is therefore desirable. Strategies to prevent TB infection in 
HIV infected children have included vaccination with Bacille Camille-Guerin (BCG) vaccine, isoniazid 
preventive therapy (IPT) and HAART. However the efficacy of BCG in HIV infected infants is not 
established [40] and may be reduced as HIV infected children have an impaired BCG-specific T-cell 
response in early life.[41] In addition BCG is unsafe in HIV infected infants with a high incidence of 
disseminated BCG disease and mortality.[42, 43]Therefore current WHO recommendations are that 
BCG should not be given to HIV infected infants at birth.[44] Isoniazid (INH), a TB medication, has 
been shown to be effective in preventing TB disease in HIV uninfected children exposed to TB [45], 
evidence which informs the current South African TB guidelines of secondary TB prophylaxis in 
children. These guidelines recommend INH prophylaxis for all children under 5 years who have a 
smear positive household TB contact. In addition they advise INH prophylaxis for all HIV infected 
children irrespective of age with a known contact due to the increased risk of TB disease as a 
consequence of HIV related immunosuppression. TB preventive therapy has been reported to be 
effective in HIV infected adults with positive tuberculin skin tests (TST), decreasing TB incidence by 
36%[46], This protective effect was consistent for all regimens: INH, INH alone, INH with rifampicin 
(RIF), RIF with pyrazinamide (PZA) and INH, RIF and PZA. However there was no impact on 
mortality.[46] IPT is currently recommended therapy for HIV infected adults with a positive or 
unknown TST who live in TB endemic areas if TB disease is excluded.[47] Moreover in a large South 
African study in HIV infected adults, IPT given to TST positive adults significantly decreased TB risk in 
adults on HAART.  HAART decreased the TB incidence by 64% (aHR=0.36, 95%CI 0.25-0.51) and IPT 
and HAART decreased TB incidence by 89% (aHR=0.11; 95% CI 0.02-0.78).[48]  
In contrast to adults, preventing TB in children is aimed at preventing primary infection rather than 
reactivation disease. However, evidence of IPT efficacy in children is inconclusive. A recent Cochrane 
review of TB preventive therapy in HIV infected children concluded that INH prophylaxis in HIV 
infected children has the potential to prevent TB in HIV infected children, but that evidence was 
lacking to guide duration of preventive therapy, use of IPT in children on HAART or the long-term 
benefits and adverse events.[49] Further clarifying the impact of IPT in HIV infected children on 
HAART is important due to the potential to reduce the burden of TB disease and resultant morbidity 























A direct search of Medline database from 1980 to June 2012 through Pubmed was undertaken. The 
search terms included:  (human immunodeficiency virus OR HIV OR human immunodeficiency 
syndrome) AND (tuberculosis OR TB) AND (preventive therapy OR chemoprophylaxis OR 
prophylaxis). The search was limited to human studies and ages 0 to 18 years. In addition reference 
lists of selected studies were reviewed for relevant information.  The full search strategy can be 















































Isoniazid preventive therapy (IPT) 
Only four publications were found:  one Cochrane review[49], two randomised placebo controlled 
trials (RCT) [39, 50] and one cohort study an extension of the Zar et al  prospective placebo 
controlled trial [51]of IPT in HIV infected children. The Cochrane review included one study by Zar et 
al. The details of this study together with the other more recently published RCT and the cohort 
analysis are summarized in Table 2. 
Impact of IPT on TB incidence and mortality 
The study outcomes of TB and mortality risk of the three studies are summarised in table 3. The 
study by Zar et al was a randomized placebo controlled trial assessing the efficacy of INH in 
preventing TB in HIV infected children living in the Western Cape, South Africa, a TB endemic 
area.[50] This study reported a significant impact on mortality and TB incidence - the mortality rate 
(12.2%) was significantly lower in those on INH (8%) compared with placebo (16%), (HR 0.46 [95% CI 
0.22 to 0.95], p=0.015), indicating a reduction in mortality of more than 50%. The incidence of TB 
(10.8%) was also significantly lower in those on INH (3.8%) versus placebo (9.9%), (HR 0.28 [95% CI 
0.1 to 0.78], p=0.005), representing a 70% reduction in the incidence of TB.[50]  The majority (91%) 
of children in this study were not on HAART at randomization as the study took place before HAART 
was widely available. Prior TB treatment was not an exclusion criteria, 16% of the cohort had been 
treated for TB prior to study enrolment. Eighty eight percent had severe immunosuppression at 
enrolment. The protective effect of INH occurred irrespective of TST status.  
 
 In contrast a second randomized placebo controlled trial of pre-exposure INH prophylaxis for TB in 
HIV infected and uninfected infants with perinatal HIV exposure, showed no decrease in TB risk 
between HIV-infected children receiving IPT and those receiving placebo.[39] This multicentre trial 
was set in South Africa and Botswana, both areas with high HIV and TB prevalence. The participants 
in this study differed significantly from the Zar et al cohort making direct comparison between the 
studies difficult (Table 2).  The participants of the Madhi study compared with the Zar cohort were 
younger (3.1 versus 24.7 months), had no previous TB exposure (0 versus 16%), were less 
immunosuppressed (7.7% versus 88% with CDC stage B or C disease) and had better nutritional 
status (-0.6 versus -1.6 median weight for age z score) at randomisation. In addition in the study by 
Madhi et al 31% (versus 7.7%) of infants were on HAART at randomisation, with 99% (versus 31%) 
receiving HAART by study closure. The incidence in this cohort of 69 (16%) cases of TB highlights the 
large burden of TB disease in HIV infected infants in TB endemic areas despite early access to 
HAART.[39]  
 
The cohort analysis of children enrolled in a randomized placebo controlled study of IPT (extended 
analysis of the Zar et al study) showed IPT to have an additional protective effect against TB in 
children on HAART.[51] This study by Frigati et al investigating the impact of dual IPT and HAART on 
TB disease in HIV infected children followed a cohort of 289 HIV infected children for a median of 
21.7 months (IQR 9 to 27.4), equivalent to 495.7 person years of follow up. A combination of IPT and 
HAART reduced TB risk by 90% (HR 0.1, 95% CI 0.04 to 0.32) in HIV infected children.  IPT alone 
reduced the risk by 78% (HR 0.22, 95%CI 0.09 to 0.53) and HAART alone by 65% (HR 0.32, 95% CI 














enrolment was associated with increased TB disease risk. This study design and execution is limited 
by the fact that the subgroups were very variable in size and follow-up periods. This may have 
impacted on the statistical power and conclusions. However this is currently the only published 
paediatric study to assess the additional protective effect of IPT in HIV infected children on HAART. 
 
Safety of IPT 
Few adverse events were found and there was no difference in event rates between the groups 
receiving INH and those receiving placebo in these studies. Of the culture confirmed cases in the 
Madhi et al study, 1 of 11 (9%) cases with culture confirmed TB was INH resistant.[39] There were no 
cases of drug resistance in the 5 cases of culture confirmed TB in the Zar et al study.[50] There were 
3 cases of INH resistance in the 19 cases of culture confirmed TB in the Frigati et al study, one of 
which had a drug resistant TB contact.[51]  
 
Adherence 



































The current data suggests that IPT may play an important role in preventing TB infection and disease 
in HIV infected children on HAART living in high TB prevalence areas. The two studies investigating 
the protective effect of IPT in HIV-infected South African children have informed the WHO’s newest 
recommendations on TB prevention and control.[47] These recommend that HIV-infected children 
older than one year of age receive IPT for 6 months irrespective of TB exposure or TST. IPT may be 
continued for up to 3 years in areas of high TB prevalence. Children less than one year of age who 
have been started on HAART for more than 3 months and are continuously screened for TB exposure 
should not receive IPT unless they have a documented TB exposure.[47]  
The different results from the two randomized controlled studies may be explained by the different 
populations studied. Zar et al studied older children with previous TB exposure, more severe 
immunosuppression, more advanced disease and lower HAART coverage.[53] The Madhi et al study 
had good screening for and follow up of household TB contacts with any infant with a contact 
receiving INH prophylaxis and exiting the study.[39] This is a potentially important difference to 
explain lack of INH efficacy and may not reflect the reality of community settings, particularly in 
areas of high TB prevalence.[53, 54] TB contact tracing and initiation of IPT is very poorly executed in 
many TB programmes.[55] In a South African study 70% of 614 children exposed to culture positive 
TB were not given INH prophylaxis despite it being recommended management.[55]Older HIV 
infected children with delayed access to HAART who live in high TB prevalence areas should receive 
IPT based on current evidence. The efficacy of IPT in HIV infected children needs to be confirmed in 
larger randomised controlled studies powered to detect a significant difference in TB incidence 
amongst HIV infected children on HAART living in high TB prevalence areas. These studies should 
also be designed to address long-term tolerability and length of protective effect.  
HAART has been reported to reduce the risk of TB disease in HIV infected adults [48] and children. 
[35, 36] A retrospective review of South African HIV infected children showed a TB incidence of 
53.3/100 person years in the 9 months prior to starting HAART, which reduced to 6.4/100 person 
years in 13.5 months of post HAART follow up.[35] A multisite retrospective analysis of HIV infected 
children attending antiretroviral clinics showed a 3 fold decrease in TB incidence in HIV infected 
children on HAART compared to HIV infected children not on HAART. [34] However, HIV infected 
children on HAART still have a higher incidence of TB than HIV uninfected children.[39] In the Madhi 
et al study, despite HAART there was a high incidence of TB in the HIV infected infants over the 18.5 
months of follow up: 12.1 cases per 100 child years in the HIV-infected compared to 4.1 cases per 
100 child years in the HIV uninfected cases.[39] The study by Frigati et al shows IPT to have an 
additional protective effect over HAART, reducing TB risk by 77% in HIV infected children on HAART 
compared to those on HAART only. This cohort lived in a setting of high TB prevalence, were older 
than the cohort from the Madhi et al study, had more advanced immunosuppression at baseline and 
had a higher rate of previous TB exposure.[39, 51] 
IPT has been shown to be safe in HIV infected children. In the studies reviewed there were few 
adverse events. Hepatotoxicity is a potential adverse event of INH therapy. [56, 57] Elevated serum 
transaminase levels occur in approximately 10% of children on IPT.[58, 59] Severe hepatotoxicity is 














children on IPT.[61] Anti-retroviral drugs are associated with a number of adverse events, in 
particular hepatotoxicity.[62, 63] Although antiretroviral drugs most often cause an asymptomatic 
elevation of transaminase levels, there have also been reported cases of fatal acute hepatitis in 
children in all classes of antiretroviral drugs. [62]Therefore there is concern about the safety of INH 
either used alone or especially concomitantly with HAART. IPT in African HIV infected adults was well 
tolerated with an INH associated toxicity incidence of 1.1%, an incidence rate the same as reported 
in HIV uninfected adults.[64]  In a retrospective cohort study of liver toxicity in HIV-infected children 
receiving IPT, severe liver injury occurred in 5% of children.[65] In a recent study of primary IPT in 
HIV infected infants on HAART followed over nearly 2 years, the incidence of significantly raised ALT 
was 0.4% and significantly raised  AST was 4%.[39] A prospective study in older HIV infected children 
enrolled in a randomised placebo controlled trial of INH prophylaxis reported a low incidence of 
hepatotoxicity in HIV infected children taking INH, with or without concomitant HAART. In this study 
297 children on IPT were followed for 559 person years. Five (1.7%) IPT related episodes of severe 
liver injury occurred, an incident rate of 0.78 per 100 person years. [66] Younger age at start of IPT 
and higher baseline CD4 count were related to increased risk of developing toxicity.[66]  
Definitive diagnosis of TB disease in children is difficult. Uncomplicated paediatric pulmonary TB is a 
pauci-bacillary disease so sputum smear microscopy is not a useful test. Culture of M tuberculosis is 
the confirmatory test but has a yield of only 20-40% in paediatric disease.[67]  TST and interferon-
gamma release assays are unable to distinguish TB infection from disease.[68] Clinical and 
radiological features are non specific but are commonly used in scoring systems to define probable 
disease. Many of these diagnostic scoring systems have been recently reviewed and found to 
significantly differ in diagnostic sensitivity.[69] Because of this difficulty there has been much 
concern  that widespread IPT may lead to an increase in INH resistance as a consequence of 
inadvertent treatment of TB disease with INH alone.  Data from the reviewed studies show no 
increase in drug resistant TB in HIV infected infants and children receiving IPT versus those receiving 
placebo. Review of adult HIV IPT programmes have found no increase in INH resistance amongst HIV 
infected adults treated with IPT and have consistently reported decreased TB risk.[48, 70, 71] The 
prevalence of drug resistance in a placebo controlled study of IPT in HIV infected and uninfected 
infants was 22.2% (95%CI 8.5-45.8) and INH mono-resistance 5.6% (95%CI 0.1-27.6) among culture-
confirmed cases.[72] There was no association between INH or placebo, or HIV infection status and 
drug resistance.[72]  The high incidence of drug resistance in this cohort is in keeping with recent 
reports of increasing drug resistance in paediatric TB cultures.[73] These studies support the safety 
of using IPT in HIV infected children but also the need to maintain surveillance for drug resistant TB 
in high prevalence settings. It is important that any IPT program includes a validated algorithm to 
reasonably exclude active disease before initiating IPT. 
 
In the setting of rising TB drug resistance the importance of medication adherence is critical. A 
concern in the consideration of programmatic implementation of IPT in children has been the 
previously reported poor implementation and adherence to IPT given to TB contacts. Both the 
implementation of [55] and adherence to secondary INH chemoprophylaxis in children has been 
reported to be very low.[74] Only 20% of children receiving IPT after exposure to a household 
contact completed more than five months of INH.[74] However, adherence to primary IPT in HIV 
infected children has been consistently reported to be over 90% in paediatric studies.[39, 52] 














limitations, particularly as there is no objective proof that the patient took the prescribed 
medication as it may have been discarded or shared.[75] This would give a false result of good 
adherence. Previous studies have reported using urine dipsticks to test urine INH metabolites, 
suggesting them to be a sensitive and an easy screening tool for INH adherence.[76, 77] However 
the sensitivity and specificity calculations were based on verbal and questionnaire report of 
adherence, neither of which are reliable measures of adherence themselves.[75] Paediatric data on 
the pharmacokinetics of INH and urine concentrations in children are lacking and would be useful in 
developing easy and more reliable screening tests for adherence to INH. 
 
 The optimal length of IPT in children to prevent either primary TB or TB re-infection is not known. A 
6 month course of INH prophylaxis has previously been described to have a prolonged protective 
effect, in excess of 9 years, in HIV uninfected Alaskan adults. However, in high prevalence settings 
re-infection after TB prophylaxis or treatment is common.[78, 79] In adult IPT studies longer courses 
of INH were associated with decreased TB re-infection, suggesting that there is significant ongoing 
transmission in the community in high prevalence settings.[70, 80] 
 
 As long as the TB exposure within a community remains high preventing TB will remain a challenge. 
Hence if IPT is to be an effective preventive strategy it must be accompanied by every effort to 
reduce the ongoing transmission within the communities. This includes improved case finding, rapid 
diagnosis, appropriate treatment and infection control.[4] Preventing paediatric HIV infection 
through comprehensive prevention of mother to child transmission programmes is of critical public 
health importance. In addition early initiation of HAART in HIV infected infants decreases mortality 
and TB risk. [39, 81] Strengthening systems to improve TB case finding, contact protection and 





































There is limited data on IPT in HIV infected children.  INH has been shown to significantly reduce TB 
incidence and death in immunosuppressed HIV infected children not on HAART living in areas with 
high TB exposure. HIV infected infants receiving early HAART and with no known exposure to TB 
were not protected by primary INH therapy. IPT protects against TB disease in HIV infected children 
with advanced disease who are taking HAART.[51] The conflicting results from the aforementioned 
studies suggest that HIV infected children’s level of immunosuppression, length of exposure and 
access to early HAART, as well as appropriate community screening and disease surveillance play a 
role in the risk of TB in HIV infected individuals and likely impact TB preventive therapy efficacy.  
Further research is needed in order to clarify efficacy of INH as a prevention strategy in older HIV 
infected children on HAART living in high TB prevalence areas with limited resources. Studies should 
address issues of long term safety and tolerability, surveillance of drug resistance and length of 
protective effect. Research assessing TB systems’ implementation of current guidelines and 
strengthening of disease surveillance, prevention and treatment is urgently needed in order to best 

































Table 1: Pubmed/Medline Search Strategy 
Search Strategy 
#1 (("hiv"[MeSH Terms] OR "hiv"[All Fields]) OR (("humans"[MeSH Terms] OR 
"humans"[All Fields] OR "human"[All Fields]) AND immune-deficiency[All Fields]) 
OR (("humans"[MeSH Terms] OR "humans"[All Fields] OR "human"[All Fields]) 
AND ("immunologic deficiency syndromes"[MeSH Terms] OR ("immunologic"[All 
Fields] AND "deficiency"[All Fields] AND "syndromes"[All Fields]) OR 
"immunologic deficiency syndromes"[All Fields] OR "immunodeficiency"[All 
Fields])) 
#2 (("tuberculosis"[MeSH Terms] OR "tuberculosis"[All Fields]) OR TB[All Fields]) 
#3 (("prevention and control"[Subheading] OR ("prevention"[All Fields] AND 
"control"[All Fields]) OR "prevention and control"[All Fields] OR ("preventive"[All 
Fields] AND "therapy"[All Fields]) OR "preventive therapy"[All Fields]) OR 
("chemoprevention"[MeSH Terms] OR "chemoprevention"[All Fields] OR 
"chemoprophylaxis"[All Fields]) OR ("prevention and control"[Subheading] OR 
("prevention"[All Fields] AND "control"[All Fields]) OR "prevention and 
control"[All Fields] OR "prophylaxis"[All Fields])) 
 








































study set within a 
randomised placebo 
controlled trial of INH 
prophylaxis. Extension 
of Zar 2007 study. 
Setting Two health care 
settings in South 
Africa 
Three South African  
and one Botswana 
health care centre 
Two health care 
settings in South Africa 
Intervention INH (10mg/kg)  or 
placebo given daily 
or three times a 
week 
INH (10-20mg/kg)  or 
placebo given daily  
Jan 2003- May2004: 
INH (10mg/kg)  or 
placebo; with and 
without ART 
June 2004 – Dec 2007: 
All children INH 
(10mg/kg) with and 
without ART 
Exclusions Known TB exposure 
requiring INH 
Any current TB contact Known TB exposure 
requiring INH 
Recruitment 44% hospitalised Hospitalised: very rare Not reported 
TB exposure on trial Open label INH and 
resume study 
Open label INH and 
exit study 
Jan 2003- May2004: 
Open label INH and 
resume study 
June 2004 – Dec 2007: 
All children on INH 
Details of participants and follow up 
Follow up – median 
(IQR)duration months   
5.7 (2-9.7) 
 
18.5 (0.25 - 27) 
 
21.7 (9.5 - 27.4) 
 
Participants  HIV infected children  
≥ 8 weeks; n=276 
Infants of HIV infected 
mothers; n=548 
HIV infected children  ≥ 
8 weeks; n=298 
Median (IQR) age in 
months at randomisation 
24.7 (9.4-51.6) 3.06 (3 – 4) 25.1 (12.4 to 49.3) 
Weight for age z score 
(IQR) 
-1.56 (-2.5, -0.43) -0.58 (-4.29, 3.07) -1.34 (-2.41,-0.43) 
CDC category B or C % 88 % 7.7% Not reported 
WHO CD4 category 3/4 Not reported Not reported 83.2% 
Median CD4 % (IQR) at 
randomisation 
20 (14-28) 28 (6 – 58) Not reported 
Previous TB  % 41/263 (16) 0  (exclusion criteria) 21/298 (7) 
HAART 
ART at baseline n (%) 23/263 (9) 171/547 (31.5) 39/298 (13) 
ART received during 
follow-up n(%) 
















Table 3 Comparison of outcomes of included studies 
Study Zar[50] Madhi[39] Frigati[51] 
Death n (%) INH: 11/132 (8%) 
Placebo: 21/131 (16%) 
HR 0.46 (95%CI: 0.22-
0.95)  
*majority not on ART 
INH: 27/273 (9.9%) 
Placebo: 17/274 (6.2%) 
HR 1.61 (95%CI: 0.88 
to 2.96) 
*majority on ART 
Not reported 
TB incidence n (%) 
and/or Hazard ratio 
(95%CI) 
INH: 5/132 (4%) 
Placebo: 13/131 (10%) 
HR 0.28 (0.1 to 0.78)  
*majority not on ART 
 
INH: 31/273 (11.4%) 
Placebo: 38/274 
(13.9%) 
*majority on ART 
INH vs. placebo: HR 
0.22(0.09,0.53) 
ART vs. placebo: HR 
0.32 (0.07 to 1.55) 
INH+ART vs. placebo: 
HR0.11 (0.04 to0.32) 
INH+ART vs. ART: HR 
0.23 (0.05 to 1) 
Overall incidence of TB 30.6 cases per 100 
children 
121 cases per 1000 
child years (95%CI, 95 
to 153) 
78 cases per 1000 child 
years  
Culture confirmed  
cases 
5/18 (28%) 11/69 (32%)  19/39 (48.7%) 
Adherence: self report 
and pill count  
%(95%CI) 
94.7% (95% confidence 
interval CI: 93.5-
95.9)[52] 
74-92% >90% [52] 
Adverse events No difference between 
INH (5;4%)and placebo 
group (8;6%) 
No difference between 
INH and placebo group 
No difference between 
INH and placebo group 
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Tuberculosis (TB) is a common cause of morbidity and mortality in HIV infected children. Isoniazid 
preventive therapy (IPT) has been shown to reduce TB incidence in HIV infected children not on 
highly active antiretroviral therapy (HAART). Data on IPT efficacy in HIV infected children receiving 
HAART is inconclusive. 
Aim 
To assess the efficacy, tolerability and safety of isoniazid (INH) compared to placebo in HIV-infected 
children on antiretroviral therapy (ART) living in a high TB prevalence area. 
Method 
A randomised placebo controlled double blind study of INH was undertaken in HIV infected children 
on ART attending three centres in Cape Town, South Africa. Children were randomised to receive 
INH or placebo either daily or thrice weekly. Participants were prospectively followed from May 
2005 to November 2011. The primary outcome measure was tuberculosis disease or death. 
Results 
One hundred and sixty seven children were randomised to receive INH (n=85) or placebo (n=82)  and 
followed for a median of 34 months (IQR 24-52). The median age was 35 months (15-65) and median 
CD4% 27 (IQR 21-34). Six (4%) children had previous TB treatment and 14 (8%) previously received 
INH prophylaxis. There was 1 death in a child on INH and none in the placebo group. Eleven (6.6%) 
cases of TB occurred during the study period; 4 (5%) in the INH and 7 (9%) in the placebo group, 
incident rate ratio (IRR) for TB was 0.5 (95%CI: 0.15 to 1.75, p=0.284). Amongst the TB cases 5 were 
culture confirmed; 2 in the INH group and 3 in the placebo group of which all were sensitive to INH. 
Very few severe adverse events (6; 2%) occurred. This study observed a total of 278.5 patient years 
during which time only one case of INH related hepatotoxicity occurred.. Adherence was good in 
both groups. Dosing frequency had no impact on TB incidence and adverse events.  
Conclusion 
IPT is safe and well tolerated in HIV infected children on concomitant ART. INH showed a trend to 
protection against TB in HIV infected children on ART. These results support the need for a larger 

























Tuberculosis (TB) and HIV are dual epidemics and a public health crisis in Southern Africa. An 
estimated 2.5 million children are living with HIV, of which 2.3 million live in Sub-Saharan Africa, with 
an estimated 230 000 child deaths from AIDS. [3] In 2010 there were an estimated 8 million incident 
cases of tuberculosis (TB) globally, 1.2 million amongst people living with HIV.  Over 1 million TB 
related deaths occurred, a third of which occurred amongst people living with HIV.[4] The African 
region accounts for 26% of the global TB burden and 82% of the TB cases among people living with 
HIV.[4]  
TB and HIV are a deleterious combination. TB is a common cause of acute and chronic respiratory 
disease and a leading cause of death amongst HIV infected children in TB endemic areas.[23, 26, 82] 
TB accelerates HIV progression through increasing viral replication.[5] Diagnosing TB, which is 
difficult in children due to the pauci-bacillary nature of the disease, is even more so in HIV infected 
children.[12, 24] Both TB and HIV treatment require extended courses of multiple drugs increasing 
the likelihood of drug interactions, adverse events and poor adherence. Immune reconstitution 
during TB treatment or on initiation of combination antiretroviral therapy (ART) may lead to a 
paradoxical worsening of symptoms further complicating the diagnosis and management of TB in 
HIV infected children. Hence preventing TB and the subsequent immune deterioration is of major 
public health importance. 
ART decreases mortality and reduce the incidence of opportunistic infections, including TB, in HIV 
infected adults and children.[35, 36, 83, 84] ART reduces TB risk and improves outcomes in HIV 
infected adults [48] and children living in high TB prevalence areas.[34-36] Although ART decreases 
TB risk, TB incidence in HIV infected as compared to uninfected infants and children remains 
high.[39] 
Isoniazid preventive therapy (IPT) effectively prevents TB infection and disease in children exposed 
to a TB smear positive household contact.[45] TB preventive therapy reduces TB risk in PPD positive 
HIV infected adults by 36%.[46]  In children the data are less clear. A randomized placebo controlled 
trial of INH prophylaxis in HIV infected children in the pre-ART era reduced all cause mortality by 
over 50% and TB by 70% in HIV infected children on INH.[50] However HIV infected infants receiving 
ART and with no previous exposure to TB received no protection from INH in a placebo controlled 
trial.[39] IPT offers additional protection against TB disease in HIV infected adults on ART [48]and is 
currently recommended by the WHO in all adults living with HIV in TB endemic areas.[4]  In a cohort 
analysis of HIV infected children living in a high TB prevalence setting  IPT offered additional 
protection against TB in older HIV infected children on ART.[51]  
The current data suggest IPT may have a significant public health impact in older HIV infected 
children in high TB prevalence settings, but confirmatory data are lacking. This study aimed to assess 
the efficacy, tolerability and safety of IPT compared to placebo in HIV-infected children on ART who 



















A longitudinal prospective double-blind placebo controlled trial comparing INH versus placebo in 
HIV-infected children on HAART attending two hospitals and one community clinic in Cape Town, 
South Africa.  Children were enrolled between May 2005 and Oct 2009 and followed until Nov 2011.  
 
Participants 
Participants were HIV infected children >8 weeks of age on ART for greater than two months. 
Inclusion criteria were: weight >2.5 kg, informed consent from a parent or legal guardian, resident in 
the area with access to transport and adherence to ART of >90%. Children were excluded if they had 
chronic diarrhoea, were currently using INH prophylaxis, had a history of prior INH hypersensitivity; 
had severe anaemia (haemoglobin less than 7 gm/dL), neutropenia (absolute neutrophil count less 
than 400 cells/µL), thrombocytopenia (platelet count less than 50 000/µL) or non reversible renal 
failure. Exposure to a household TB contact was also an exclusion criterion. Children with prior 
history of TB treatment or prophylaxis were eligible for inclusion. TB was excluded prior to 
randomization with symptom and contact history, tuberculin skin test (PPD, 2 TU RT23, Staten 
Serum Institut, Copenhagen, Denmark), chest radiograph and two induced sputa. Any child found to 
have TB was treated as per South African National TB treatment guidelines.[85] Once treatment had 
been completed the participant was then eligible for enrolment. Children were followed up two 
weekly for the first month, monthly for the first 6 months and then 3 monthly.  
 
Allocation and prophylaxis 
Within each of the three sites children were randomised at study entry to receive either INH or 
placebo either thrice weekly or daily according to variable blocked randomization lists prepared by 
the trial statistician. These lists were sent to the study pharmacist in sealed opaque envelopes. 
Participants were allocated a sequential number by the study nurse at enrolment and then 
sequentially allocated to treatment group by the pharmacist according to the pre-prepared lists. The 
dose of INH was 10 mg/kg/dose with a variability of 8-12 mg/kg determined according to whether 
half or quarter tablets were required. Placebo had an identical appearance to INH tablets and was 
administered in a double blind manner.  
 
Investigations and study end points 
At the baseline visit a detailed history, examination and clinical HIV staging was done. At follow up 
visits thereafter a symptom and contact history was taken and a physical examination completed. A 
full blood count (FBC), liver function tests (ALT) and urea and electrolytes were performed at 
baseline and FBC and ALT six monthly. The absolute number and percentage of CD4 cells and viral 
load were measured at study entry and then six monthly. PPD skin testing was repeated six monthly 
if the prior test was negative. A chest radiograph was performed. Additional chest radiographs were 
taken if there was concern of current TB disease or otherwise clinically indicated. The chest 
radiographs were reported according to a standardized format by a single radiologist who was 
blinded to the prophylactic regimen to which the child was allocated. 
In addition, at each visit symptoms of adverse reactions to INH prophylaxis, details of intercurrent 
clinic or hospital visits were recorded. Diagnosis of TB: Children were classified as having definite 
tuberculosis if they were culture positive for M tuberculosis. Probable tuberculosis was diagnosed 
when chest radiography suggested tuberculosis (lymphadenopathy, military pattern, pleural 
effusion, bronchial compression, or parenchymal infiltrate) and the child had at least one of: a 
positive tuberculin skin test result, a history of a close contact with tuberculosis, loss of weight or 
failure to gain weight within the previous three months, or a positive smear result for acid fast 
bacilli. The diagnosis of definite or probable TB was made by the treating doctor and independently 
reviewed by an experienced clinician using the clinical, radiological and laboratory data and blinded 















Development of TB during the trial or exposure to a household TB contact: If a child developed 
pulmonary TB while on the study, the prophylaxis was stopped. The child was placed on TB 
treatment in accordance with local guidelines (INH, rifampicin (RIF) and pyrazinamide two month 
intensive phase followed by INH and RIF for 4 months as continuation phase) and modified if 
necessary when sensitivities were available. Children taking lopinavir/ritonavir based ART had 
boosted ritonavir doses for duration of concomitant RIF therapy.[27] The INH/placebo prophylactic 
regimen was resumed once TB treatment was completed. If a household contact developed TB, the 
participants were investigated for TB disease (TST, radiograph and induced sputum or 3 gastric 
washings).  Children without TB were given 6 months INH prophylaxis after which the assigned 
INH/placebo was restarted with blinding maintained. 
Adherence 
Patients were provided with an adequate medication supply and were requested to return empty 
INH containers. Adherence for INH / placebo was assessed through pill count of returned tables.  
Statistical Analysis 
This study followed after a larger study of INH prophylaxis in HIV infected children, most of who 
were not on HAART as the study started before its widespread availability. [50] Based on an 
incidence rate for TB in children from that study of 0.14/year (0.23 per year in placebo versus 0.07 
per year in INH groups) a sample size of more than 300 children in each arm would have been 
required to detect a difference in the TB-free survival curves (assuming a more conservative hazard 
ratio of .5) between the groups with 90% power and a 0.05 level of significance. As this very large 
sample size was not feasible due to the funding and resource constraints available for the study, we 
planned to enroll 150 children to provide preliminary information on the efficacy, safety, tolerability 
and adherence to INH prophylaxis in children on HAART so as to inform a potentially larger study. 
All analyses were by intention to treat. We used Kaplan-Meier analyses to assess time to outcome, 
made comparisons with one sided log rank test and used Poisson and binomial regression models to 
estimate relative risks (incidence rate ratios for Poisson) of study outcomes: TB disease, adverse 
events and intercurrent events by randomization groups (drugs and regimen frequency) adjusted for 
stratification by site. 
Consent 
Written informed consent was obtained from the parent or legal guardian. This was undertaken in 
the parents’ language of pref rence. The study was approved by the Research and Ethics 
Committees of the Faculty of Health Sciences, University of Cape Town (ethics no. 299/2005) and 
Stellenbosch University (ethics no. 2002C/073). 
  
Results 
One hundred and sixty seven children were enrolled at 3 sites (27 at Paarl TC Newman Hospital, 121 
at Red Cross Children’s Hospital and 19 at Tygerberg Hospital); 82 (49%) children were randomised 
to receive placebo and 85 (51%) to receive INH. There was 1 death in the INH group and 51 children 
were lost to follow-up: 24 could not be contacted, 24 relocated, 3 withdrew consent (Figure 1). The 
median follow up was 34 months (IQR 1 to 79). Baseline demographics were similar but the placebo 
group was six months older than the INH group, longer and heavier at baseline (Table 1). Both 
groups had similar CD4%, disease staging, ALT levels and viral loads at baseline. Twenty-six (16%) 
children had positive TST at enrolment, more in the placebo than treatment group. Six (4%) children 
had received prior treatment for TB and 14 (8%) had received INH prophylaxis (Table 1). 
 
TB incidence: Eleven children developed TB during the study period, 7 (8.5%) in the placebo group 














and 3/7 (43%) in the placebo group; and 6 were probable TB cases. (Table 2) The total months of 
follow up for TB incidence was 2879 in the placebo group and 3276 in the INH group. This translates 
into 2.92 cases of TB annually per 100 children in the placebo and 1.46 cases of TB annually per 100 
children in the INH group. The incident rate ratio for TB in INH as compared to the placebo group 
was 0.51 (95%CI: 0.15 to 1.75, p=0.284. Children taking medication daily had more TB events 7 in 
3295 person years (2.5 cases annually per 100 children) as compared to those taking medication 
thrice weekly 4 in 2860 person months (1.7 cases annually per 100 children) / with an IRR 1.54 (95% 
CI: 0.45 to 5.27; p=0.49).  Most TB events (8; 73%) occurred during the first 18 months of the follow 
up, including all 7 events in the placebo group. During the subsequent follow up (months 19 to 79) 
there were 3 more events in children taking INH (Figure 2). 
Adherence: Adherence was stable and good throughout the study (Table 3). The mean adherence 
was 97% (SD 6.8). The mean adherence in the placebo group was 97.8% (SD 6.4) compared to 96% 
(SD 7) in the INH group, p=0.06. The adherence in the group taking medication daily was slightly 
better than that in the thrice weekly group, 98% compared to 95.8% (P=0.04). There was no 
interaction between treatment and dosing schedule when accounting for factorial design (p=0.697,). 
Adherence had no association with TB outcome (IRR 0.97, 95%CI 0.87-1.07, p=0.578). 
Adverse events: There were very few severe adverse events (Table 3). Four of 6 events were 
temporary transaminitis, three of which were unrelated to study medication. One case of 
transaminitis may have been related to study medication, when medication was stopped, 
transaminitis settled and the medication was safely reintroduced. There was one case of 
trimethoprim-sulphamethoxazole hypersensitivity rash and one case of premature telarche, neither 
of which were related to the study medication. Taking into account follow up time, intercurrent 
open label prophylaxis of placebo assigned participants and intercurrent TB treatment, this study 
observed a total of 278.5 patient years of daily or thrice weekly INH in HIV infected children on 
HAART. During this time only one case of INH related transaminitis occurred.  
Hospital admissions:  There were 53 intercurrent hospitalizations in 29 children during study follow 
up, 13 children in the placebo group and 16 children on isoniazid, p=0.68 (Table 3). The relative risk 
of hospitalization for isoniazid versus placebo was 1.34 (95%CI 0.74-2.4, p=0.3) and for dosing 
regimen, daily versus thrice weekly 1.22 (95%CI 0.69-2.21, p=0.48).  
Discussion 
This study addresses the impact of INH on TB disease in an important group of HIV infected children, 
namely older children on ART living in areas of high TB prevalence. In this study the TB incidence in 
the placebo group, compared to the INH group (2.8 versus 1.5 cases annually per 100 children) 
suggests an INH protective effect. Larger studies are needed to assess INH efficacy in this patient 
population. No difference in TB incidence between children receiving prophylaxis daily compared to 
3 times a week occurred, similar to the findings of a prior study in which the prophylaxis dosing 
regimens of daily or 3 times weekly INH had similar efficacy.[50] The TB incidence rates in the 
placebo  and INH groups are much lower than previously reported by Zar et al in a prior study of HIV 
infected children in the same region (23.4 and 7.2 cases annually per 100 children in HIV infected 
children receiving placebo and INH respectively) however most children were not on ART.[50] This 
result is consistent with the protective effect of ART against TB. In addition the children in this study 















the children were older, all on ART and better nourished.[50] All three studies were set in high TB 
prevalence areas but, in contrast to the Madhi et al study, where close surveillance of and use of INH 
in any infant with a TB contact was undertaken, children in the current study relied in part on TB 
contact tracing and management from local TB programmes.[39] TB contact tracing and 
management has been shown to be poor in many TB programmes.[55, 74]  As with the Zar et al 
study, the current study more closely represents the real life conditions and exposures of HIV 
infected children in high TB prevalence areas. Of the 4 cases of TB in the INH group, only one case 
occurred within the first 18 months of follow-up. This may suggest a waning in protective effect of 
INH after 18 months.  
The main limitation of this study is the small sample size providing inadequate power to detect a 
significant difference in TB incidence between the INH and placebo groups. Diagnosing TB in children 
is difficult due to the pauci-bacillary nature of the disease, with culture of M tuberculosis being the 
definitive test.  Only 5 cases of culture confirmed TB occurred. The use of diagnostic algorithms is 
limited [69] and it is conceivable that some of the children diagnosed with probable TB may not have 
had TB. However the diagnosis of TB was reviewed by an independent paediatric TB expert who was 
blinded to randomisation and all were treated for TB with clinical improvement. 
 
All cases of culture-confirmed TB were sensitive to INH, providing evidence of its safety when used 
long term and is consistent with prior studies of IPT in HIV infected children have reported similar 
results.[39, 50, 51] In a study of IPT in HIV infected and uninfected infants there were 5 cases of INH 
resistance amongst 19 cases of culture confirmed TB, 2 of which occurred in the INH group and 3 in 
the placebo group.[39] Large adult studies of IPT have shown no increased risk of INH resistant TB in 
HIV infected adults taking IPT.[48, 70, 71] Surveillance must however be maintained and a validated 
algorithm to exclude active TB disease followed before initiating IPT. 
 
Adherence in this cohort was excellent, consistent with previous reports of primary IPT in HIV 
infected children in IPT studies.[52] These adherence rates are much higher than those described 
with secondary INH prophylaxis in which only 36% of children completed the prescribed 6 months of 
INH.[74] IPT adherence may be lower in a programmatic setting. However these HIV infected 
children taking IPT already had excellent adherence to HAART regimens, which may have facilitated 
good adherence to IPT. In addition caregivers may have seen the IPT as part of a regimen for treating 
an illness rather than perceiving the more difficult concept of a preventive strategy.  
A strength of this study is the long time of follow-up, during which there was only 1 episode of INH 
related hepatotoxicity. This rate is even lower than the recently reported incident rate of 0.78 per 
100 person years in another  INH prophylaxis placebo controlled trial in older HIV infected 
children.[66] This is consistent with previous reports of IPT safety in HIV infected infants and children 
on HAART.[39, 65]  
In conclusion this study, the first randomised controlled trial to assess INH preventive therapy in 
older HIV infected children on HAART, showed a trend to protection against TB. INH is safe and well 
tolerated in HIV infected children on concomitant HAART. These results support the need for a larger 

















Figure 1: Enrolment, randomization and follow-up of study cohort 
 
Figure 2 Time to TB diagnosis in the INH and placebo groups 
 
167 children randomized 
27  from Paarl TC Newman clinic  
121 from Red Cross War Memorial 
Children's Hospital 
19 Tygerberg Hospital 
85 assigned to receive INH: 
40 three x week dosing 
45 daily dosing 
 
24 loss to follow up: 
10 could not be contacted 
11 relocated 
3 parental request 
1 death 
85 included in analysis 
82 assigned to receive placebo: 
39 three x week dosing 
43 daily dosing 
 
27 loss to follow up: 
14 could not be contacted 
13 relocated 







Cumulative Failure Probability 
85 70 37 15 0 trt = INH 
82 55 30 9 0 trt = Placebo 
Number at risk 
0 20 40 60 80 
Months since enrolment 
trt = Placebo trt = INH 















Table 1 Baseline demographic data for children 
 Placebo INH 
N (%) 82 (49) 85(51) 
Dosage daily n (%) 38 (48) 40 (47) 
Male n (%) 42 (51) 41 (48) 
Age in months median (IQR) 38 (15 to76) 32 (17 to63) 
CD4 count median (IQR) 1159 (866 to1457) 1147 (783 to1749) 
CD4% median (IQR) 27 (22 to34) 27 (19 to33) 
Weight for age z-scores median (IQR) -0.95(-1.72 to-0.19) -1.11(-2.3 to -0.25) 
Height for age z-score median (IQR) -1.22(-2.3 to-0.6) -1.41 (-2.67 to-0.37) 
Weight for height z-score median (IQR) 0.12(-0.44 to-1.08) 0.23(-0.57 to 0.82) 
ALT1 mean (sd) 22 (9) 24 (16) 
HIV viral load LDL2 n (%) 58 (69.5) 57 (67.0) 
HIV viral load log median (IQR) 0 (0 to670) 0 (0 to530) 
WHO3 classification   
Stage 2 n (%) 6 (7) 6 (7) 
Stage 3 n (%) 33 (40) 37 (44) 
Stage 4 n (%) 43 (52) 42 (49) 
Months on ART median (IQR) 34.0 (19.8 to 49.8) 31.5 (21.8 to 50.5) 
   
TST4  positive n (%) 14 (17) 12 (14) 
Previous TB treatment n (%) 4 (5) 2 (2) 
Previous TB prophylaxis n (%) 8 (10) 
 
6 (7) 
1alanine transferase, 2lower than detectable level, 3World Health Organisation, 4tuberculin skin test 
 
Table 2 Incidence of TB in children  
 Placebo INH 
 n=82  n=85 
   
Mean months of follow up (sd) 35 (19.5) 38.5 (21.4) 
Total months of follow up 2879 3276 
   
TB incidence n (%) 7 (8.5) 4 (4.7) 
Confirmed TB n (%) 3 (43) 2 (50) 
Probable TB n (%) 4 (57) 2 (50) 
   
Frequency of dose   
Thrice weekly 2/39 (5) 2/40 (5) 
Daily n (%) 5/43 (11) 2/45 (4) 
















Table 3 Adherence, intercurrent hospital admissions and adverse events in children by dosing 
schedules 









Adherence %  
mean(SD) 
96 (7) 97.8 (6.4) P=0.06 98 (7.3) 95.8 (6) P=0.04 
       
   Relative 
risk (95%CI) 
  Relative risk 
(95%CI) 
Hospital 
admissions n (%) 
16 (55) 13 (45) 1.22 (0.64-
2.35) 
13 (45) 16 (55) 0.69 (0.36-
1.32) 
       
   Fisher 
exact 
  Fisher exact 
Adverse events 4 (67) 2 (33) P=1.0 3 (50) 3 (50) P=1.0 
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PART D APPENDICES 
 Appendix 1 Consent and Information forms 
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Appendix 2 Data capture form for each study visit  
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